AU2019317625B2 - Pyrrolopyrimidine ITK inhibitors - Google Patents
Pyrrolopyrimidine ITK inhibitors Download PDFInfo
- Publication number
- AU2019317625B2 AU2019317625B2 AU2019317625A AU2019317625A AU2019317625B2 AU 2019317625 B2 AU2019317625 B2 AU 2019317625B2 AU 2019317625 A AU2019317625 A AU 2019317625A AU 2019317625 A AU2019317625 A AU 2019317625A AU 2019317625 B2 AU2019317625 B2 AU 2019317625B2
- Authority
- AU
- Australia
- Prior art keywords
- pyrrolo
- amino
- pyrimidin
- prop
- methylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717400P | 2018-08-10 | 2018-08-10 | |
| US62/717,400 | 2018-08-10 | ||
| PCT/US2019/046182 WO2020033955A1 (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine itk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019317625A1 AU2019317625A1 (en) | 2021-02-18 |
| AU2019317625B2 true AU2019317625B2 (en) | 2025-02-27 |
Family
ID=69405523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019317625A Active AU2019317625B2 (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine ITK inhibitors |
Country Status (13)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| JP7591500B2 (ja) * | 2018-08-10 | 2024-11-28 | アクラリス セラピューティクス,インコーポレイテッド | ピロロピリミジンitk阻害剤 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| PH12021552036A1 (en) | 2019-05-02 | 2022-05-23 | Aclaris Therapeutics Inc | Substituted pyrrolopyridines as jak inhibitors |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| TW202207918A (zh) * | 2020-05-14 | 2022-03-01 | 美商施萬生物製藥研發Ip有限責任公司 | 腸道選擇性jak3抑制劑的投與 |
| KR102560138B1 (ko) * | 2020-06-15 | 2023-07-27 | 경북대학교 산학협력단 | 신경교세포 표현형 기반의 siRNA 다중 스크리닝을 통해 선별된 신경교세포 인산화효소의 신경염증 조절 용도 |
| CN114887080B (zh) * | 2020-12-08 | 2023-10-31 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| CN113350346B (zh) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | 长春新碱在预防或治疗心肌纤维化中的应用 |
| KR20230019801A (ko) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물 |
| CN113571191A (zh) * | 2021-08-31 | 2021-10-29 | 复旦大学附属中山医院 | 免疫检查点抑制剂相关mace发生风险的预测方法 |
| WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| EP4615440A1 (en) * | 2022-11-08 | 2025-09-17 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of itk mediated conditions |
| CN116115760A (zh) * | 2022-12-15 | 2023-05-16 | 浙江大学 | Eed抑制剂在制备治疗神经免疫性疾病药物中的应用 |
| AU2024415240A1 (en) * | 2023-12-28 | 2026-07-30 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| AU2024415877A1 (en) * | 2023-12-28 | 2026-07-30 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| CN117982685B (zh) * | 2024-01-26 | 2025-05-30 | 北京大学人民医院 | 用于骨肉瘤检测的光学分子成像探针及其制备方法和应用 |
| WO2025181247A1 (en) * | 2024-02-28 | 2025-09-04 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| WO2025235366A1 (en) * | 2024-05-07 | 2025-11-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of atopic dermatitis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| US20150158864A1 (en) * | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides |
| WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
| WO2016178110A1 (en) * | 2015-05-01 | 2016-11-10 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
| WO2018004306A1 (en) * | 2016-06-30 | 2018-01-04 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| US20180055846A1 (en) * | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2277954A1 (en) | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Jak−3インヒビターを用いたc−jun発現の阻害方法 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| JP2008545660A (ja) | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| US20100105661A1 (en) | 2007-01-12 | 2010-04-29 | Astellas Pharma Inc. | Condensed pyridine compound |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| BR112014002472A2 (pt) | 2011-08-12 | 2017-04-11 | Nissan Chemical Ind Ltd | "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento" |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| US9206188B2 (en) * | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
| AU2016209046A1 (en) * | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| US10159662B2 (en) | 2015-12-11 | 2018-12-25 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| JP7591500B2 (ja) * | 2018-08-10 | 2024-11-28 | アクラリス セラピューティクス,インコーポレイテッド | ピロロピリミジンitk阻害剤 |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
| PH12021552036A1 (en) | 2019-05-02 | 2022-05-23 | Aclaris Therapeutics Inc | Substituted pyrrolopyridines as jak inhibitors |
| US11602536B2 (en) | 2019-06-10 | 2023-03-14 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
| WO2021022178A1 (en) | 2019-07-31 | 2021-02-04 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
-
2019
- 2019-08-12 JP JP2021531626A patent/JP7591500B2/ja active Active
- 2019-08-12 EP EP19846283.0A patent/EP3833350A4/en active Pending
- 2019-08-12 CN CN201980066579.2A patent/CN112823005B/zh active Active
- 2019-08-12 KR KR1020217007377A patent/KR102849047B1/ko active Active
- 2019-08-12 WO PCT/US2019/046182 patent/WO2020033955A1/en not_active Ceased
- 2019-08-12 BR BR112021002479-4A patent/BR112021002479A2/pt not_active IP Right Cessation
- 2019-08-12 SG SG11202100525SA patent/SG11202100525SA/en unknown
- 2019-08-12 US US16/538,354 patent/US11021482B2/en active Active
- 2019-08-12 CA CA3109192A patent/CA3109192A1/en active Pending
- 2019-08-12 AU AU2019317625A patent/AU2019317625B2/en active Active
- 2019-08-12 CN CN202411055491.XA patent/CN119080779A/zh active Pending
- 2019-08-12 MX MX2021001558A patent/MX2021001558A/es unknown
-
2021
- 2021-01-25 PH PH12021550187A patent/PH12021550187A1/en unknown
- 2021-02-02 IL IL280593A patent/IL280593A/en unknown
- 2021-04-21 US US17/236,531 patent/US11820775B2/en active Active
-
2023
- 2023-10-24 US US18/383,301 patent/US12297203B2/en active Active
-
2024
- 2024-11-18 JP JP2024200937A patent/JP2025037892A/ja not_active Withdrawn
-
2025
- 2025-04-18 US US19/182,994 patent/US20260035373A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| US20150158864A1 (en) * | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides |
| WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
| WO2016178110A1 (en) * | 2015-05-01 | 2016-11-10 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
| WO2018004306A1 (en) * | 2016-06-30 | 2018-01-04 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| US20180055846A1 (en) * | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US11021482B2 (en) | 2021-06-01 |
| US12297203B2 (en) | 2025-05-13 |
| WO2020033955A1 (en) | 2020-02-13 |
| CN112823005B (zh) | 2024-08-20 |
| EP3833350A1 (en) | 2021-06-16 |
| JP7591500B2 (ja) | 2024-11-28 |
| US20260035373A1 (en) | 2026-02-05 |
| IL280593A (en) | 2021-03-25 |
| JP2021534244A (ja) | 2021-12-09 |
| CN112823005A (zh) | 2021-05-18 |
| BR112021002479A2 (pt) | 2021-07-27 |
| US11820775B2 (en) | 2023-11-21 |
| US20240132505A1 (en) | 2024-04-25 |
| US20200048262A1 (en) | 2020-02-13 |
| SG11202100525SA (en) | 2021-02-25 |
| EP3833350A4 (en) | 2022-05-18 |
| KR20210044822A (ko) | 2021-04-23 |
| MX2021001558A (es) | 2021-04-28 |
| KR102849047B1 (ko) | 2025-08-22 |
| CA3109192A1 (en) | 2020-02-13 |
| CN119080779A (zh) | 2024-12-06 |
| AU2019317625A1 (en) | 2021-02-18 |
| US20220348579A1 (en) | 2022-11-03 |
| JP2025037892A (ja) | 2025-03-18 |
| PH12021550187A1 (en) | 2022-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12297203B2 (en) | Pyrrolopyrimidine ITK inhibitors | |
| AU2023248127B2 (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| US11434233B2 (en) | Heterocyclic inhibitors of ATR kinase | |
| WO2021022186A1 (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
| JP2019535664A (ja) | ユビキチン特異的プロテアーゼ7の阻害剤としてのピペリジン誘導体 | |
| WO2019090143A1 (en) | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same | |
| WO2021022178A1 (en) | Substituted sulfonamide pyrrolopyridines as jak inhibitors | |
| WO2019178590A1 (en) | Heterocyclic inhibitors of atr kinase | |
| US10316038B2 (en) | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | |
| HK40028148A (en) | Heterocyclic inhibitors of atr kinase | |
| HK40028148B (en) | Heterocyclic inhibitors of atr kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |